fbpx

Weekly Top News – IBD – June 17, 2019

Entyvio (vedolizumab) / Takeda
Phase 3 study of MLN0002 (300 mg) in treatment of ulcerative colitis (clinicaltrialsregister.eu) – Jun 16, 2019 – P3; N=292; Sponsor: Takeda

 

Entyvio (vedolizumab) / Takeda
Phase III Study of MLN0002 (300 mg) in Treatment of Crohn’s Disease (clinicaltrials.gov) – Jun 12, 2019 – P3; N=157; Completed; Sponsor: Takeda; Active, not recruiting –> Completed

 

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Skyrizi sales projection: $150M in H2 2019 (Zacks) – Jun 12, 2019 – A subscription to Thomson ONE is required to gain full access to report 67443474; Page no: 6; REPORT TITLE: “AbbVie Inc.(ABBV) Zacks Company report”; AUTHOR: Research Department; DATE: 06/03/2019

 

Xeljanz (tofacitinib) / Pfizer
Xeljanz US sales projection: $2.7B in 2024 (Infinata) – Jun 15, 2019 – A subscription to Thomson ONE is required to gain full access to report 67021619; Page no: 10; REPORT TITLE: “Pfizer, Inc. – Company report”; AUTHOR: Infinata, et al; DATE: 06/03/2019

 

Humira (adalimumab) / Eisai, AbbVie
Humira sales projection: Guidance of $21B in 2020 (Credit Suisse) – Jun 10, 2019 – A subscription to Thomson ONE is required to gain full access to report 67443417; Page no: 16; REPORT TITLE: “US Pharmaceuticals industry overview – June 2019”; AUTHOR: Divan, Vamil, et al; DATE: 06/03/2019

 

ozanimod (RPC1063) / Celgene
Ozanimod sales projection: $1.8B (consensus: $1.3B) by 2023 (Barclays) – Jun 12, 2019 – A subscription to Thomson ONE is required to gain full access to report 67458401; Page no: 1; REPORT TITLE: “CELG/BMY – Thoughts on Ozanimod NDA acceptance”; AUTHOR: Meacham, Geoffrey, et al; DATE: 06/06/2019

 

Perianal Fistula (PAF) Validation and Burden of Illness Study (clinicaltrials.gov) – Jun 12, 2019 – P; N=600; Not yet recruiting; Sponsor: Takeda

No Comments

Post a Comment

Comment
Name
Email
Website